drugset / Trial / NCT01641536
Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an open label, dose escalation study using the classical 3+3 design to determine the MTD of HB-110 and assess the safety, immunogenicity and efficacy of HB-110 DNA therapeutic vaccine administered by Electroporation in combination with Entecavir in chronic hepatitis B patients.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-12
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB-110 | Vaccine | 1 mg | Other |
| Subject | HB-110 | Vaccine | 2 mg | Other |
| Subject | HB-110 | Vaccine | 4 mg | Other |
| Background | Entecavir | Small molecule | 0.5 mg | Oral |